Navigation Links
WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release

Earnings Conference Call to be Held on May 15, 2009 at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong)

SHANGHAI, May 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2009 on May 15, 2009 Shanghai time, and after the U.S. market closes on Thursday, May 14, 2009 New York time.

(Logo: )

The earnings release will be available on the investor relations section of its website at

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Friday, May 15, 2009, to discuss its 2009 first-quarter financial results and recent business activities. The conference call may be accessed by calling:

        United States: 1-866-519-4004
        China (Landline): 800-819-0121
        China (Mobile): 400-620-8038
        Hong Kong: 800-933-053
        United Kingdom: 0-808-234-6646
        International: +65-6735-7955
        Conference ID: 96870349
        Web PIN: 8656

A telephone replay will be available two hours after the call's completion at:

        United States: 1-866-214-5335
        China North: 10-800-714-0386
        China South: 10-800-140-0386
        Hong Kong: 800-901-596
        United Kingdom: 0-800-731-7846
        International: +61-2-8235-5000
        Passcode: 96870349

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit:

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
2. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
3. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
4. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
5. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
6. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
7. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
8. Pharmatech 2.0: Introducing Pharmatech Oncology
9. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
10. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
11. WuXi PharmaTech Announces Third Quarter 2008 Results
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... The New ... age children in the areas of Science, Technology, Engineering and Mathematics. The skill ... economy, and the program aims to increase the number of students who pursue ...
(Date:10/12/2015)... and BRUSSELS , Oct. 12, 2015 ... UCB) today presented additional findings from an exploratory sub-study of ... findings were presented today in an oral plenary session at ... Annual Meeting in Seattle . ... --> The small exploratory sub-study data showed that, at ...
(Date:10/12/2015)... Group, Inc. (NASDAQ: MDXG ), the leading regenerative ... to develop and market advanced products and therapies for ... and the Dental sectors of healthcare, announced today the ... Company has been dismissed by the court.  ... "As we suspected, this case was brought by an ...
(Date:10/12/2015)... Minn. , Oct. 12, 2015  Rebiotix ... Administration (FDA) has designated its lead Microbiota Restoration ... the treatment of recurrent Clostridium difficile ... (GI) infection that causes 29,000 deaths in the ... stage biotechnology company that was founded to revolutionize ...
Breaking Biology Technology:
(Date:10/13/2015)... Research and Markets ( ) has ... & Identification Market - Estimation & Forecast (2015-2020)" ... --> The biometric market value is ... $2.06 billion in 2020 at an estimated CAGR of ... India . Growing digitization in the government sector ...
(Date:10/12/2015)... Hoyos Labs , ... will introduce its new biometric four-finger (4F) ... providing an unprecedented level of security / ... new biometric standard for secure transactions (BOPS). ... financial services to healthcare are implementing Hoyos, ...
(Date:10/8/2015)... JOSE, Calif. , Oct. 8, 2015 /PRNewswire/ ... developer of human interface solutions, announced today that ... quarter of fiscal 2016 on Thursday, October 22, ... will host a corresponding conference call for analysts ... ET), during which management may discuss forward-looking information.  ...
Breaking Biology News(10 mins):